Provided by Tiger Trade Technology Pte. Ltd.

Oculis

28.57
+0.03000.11%
Volume:266.45K
Turnover:7.65M
Market Cap:1.63B
PE:-10.49
High:28.90
Open:28.53
Low:28.42
Close:28.54
52wk High:29.36
52wk Low:14.00
Shares:57.07M
Float Shares:46.06M
Volume Ratio:0.81
T/O Rate:0.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7247
EPS(LYR):-2.3426
ROE:-92.19%
ROA:-33.35%
PB:9.59
PE(LYR):-12.20

Loading ...

Company Profile

Company Name:
Oculis
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
49
Office Location:
Bahnhofstrasse 20,Zug,Zug,Switzerland
Zip Code:
6300
Fax:
- -
Introduction:
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.